stavudine – kdc

CLINICAL USE

Nucleoside reverse transcriptase inhibitor:Treatment of HIV in combination with other antiretroviral drugs

DOSE IN NORMAL RENAL FUNCTION

<60 kg: 30 mg twice daily>60 kg: 40 mg twice daily

PHARMACOKINETICS

Molecular weight :224.2

%Protein binding :<1

%Excreted unchanged in urine : 40

Volume of distribution (L/kg) :0.5

half-life – normal/ESRD (hrs) :1–1.5/5.5–8

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

26–50 <60 kg: 15 mg twice daily >60 kg: 20 mg twice daily<25 <60 kg: 15 mg daily >60 kg: 20 mg daily

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in GFR<25 mL/min

HD :Dialysed. Dose as in GFR<25 mL/min

HDF/high flux :Dialysed. Dose as in GFR<25 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR=26–50 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antivirals: zidovudine may inhibit intracellular activation – avoid concomitant use; increased risk of side effects with didanosine; effects possibly inhibited by ribavirinCytotoxics: effects possibly inhibited by doxorubicin; increased risk of toxicity with hydroxycarbamide – avoid concomitant use

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

Administer at least an hour before food

OTHER INFORMATION

Clearance by haemodialysis is 120 mL/min Lactic acidosis, sometimes fatal, has been reported with the use of nucleoside analoguesPatients with ERF are more likely to develop peripheral neuropathy.

Tags: post-by-auto-php